CN112458165A - 一种阿尔茨海默病的预测标志物、检测试剂盒及应用 - Google Patents
一种阿尔茨海默病的预测标志物、检测试剂盒及应用 Download PDFInfo
- Publication number
- CN112458165A CN112458165A CN202011571363.2A CN202011571363A CN112458165A CN 112458165 A CN112458165 A CN 112458165A CN 202011571363 A CN202011571363 A CN 202011571363A CN 112458165 A CN112458165 A CN 112458165A
- Authority
- CN
- China
- Prior art keywords
- marker
- mir
- hsa
- mirna
- mci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 51
- 239000003550 marker Substances 0.000 title claims abstract description 35
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 108091065165 Homo sapiens miR-106b stem-loop Proteins 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 108091070501 miRNA Proteins 0.000 description 34
- 239000002679 microRNA Substances 0.000 description 34
- 208000010877 cognitive disease Diseases 0.000 description 30
- 208000027061 mild cognitive impairment Diseases 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 22
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000012165 high-throughput sequencing Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 108020005093 RNA Precursors Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006741 behavioral dysfunction Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
本发明涉及一种生物技术领域,尤指一种阿尔茨海默病的预测标志物、检测试剂盒及应用,所述的标志物为hsa‑miR‑106b‑3p,所述试剂盒包含所述的标志物hsa‑miR‑106b‑3p;本发明将hsa‑miR‑106b‑3p作为阿尔茨海默病早期预测的标志物,并可应用于检测试剂盒的制备中实现阿尔茨海默病早期的辅助诊断。
Description
技术领域
本发明涉及一种生物技术领域,尤指一种阿尔茨海默病的预测标志物、检测试剂盒及应用。
背景技术
阿尔兹海默病(AD)是一种进行性认知、行为功能失常的中枢神经系统的退行型疾病,是最常见的痴呆类型,早期和准确地诊断AD至关重要,这可以为患者早期治疗从而减缓疾病的进展,因此临床医生提出轻度认知功能障碍(MCI)的概念,MCI是指有轻度记忆力或认知能力损害但未达到AD诊断标准的老年人,被认为是AD的早期阶段。淀粉样蛋白脑脊液(CSF)中的Aβ和高磷酸化tau水平已被建议作为AD的诊断标志物;但是,进一步研发侵入性更小的检测方法(例如血液测试)识别生物标志物具有更加广阔的前景,目前迫切需要研发可用于AD早期诊断的简单、廉价、无创且易于获得的诊断工具。
本发明研究发现miRNA可在血浆中稳定存在,被认为是疾病的有效潜在诊断标志物,循环miRNA水平已被提出可作为许多疾病的潜在诊断工具。因此在本发明中,我们利用高通量测序和荧光定量PCR(qPCR)获得CN、MCI、AD患者血浆miRNA的表达水平,以进一步筛选及评估miRNA用作AD早期诊断标志物的潜力。
发明内容
为解决上述问题,本发明旨在公开一种生物技术领域,尤指一种阿尔茨海默病的预测标志物、检测试剂盒及应用。
为实现上述目的,本发明采用的技术方案是:
一种阿尔茨海默病早期预测的标志物,其特征在于,所述的标志物为hsa-miR-106b-3p。
优选地,所述标志物hsa-miR-106b-3p的核苷酸序列如下所示:
RT:GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAGCAGCA。
优选地,合成所述标志物hsa-miR-106b-3p的引物为:
F:CCGCACTGTGGGTACTT;R:GTGCAGGGTCCGAGGT。
一种阿尔茨海默病检测试剂盒,其特征在于,所述试剂盒包含以上所述的标志物hsa-miR-106b-3p。
所述标志物在制备阿尔茨海默病检测试剂盒中的应用。
本发明的有益效果体现在:本发明将hsa-miR-106b-3p作为阿尔茨海默病早期预测的标志物,并可应用于检测试剂盒的制备中实现阿尔茨海默病早期的辅助诊断。
本发明通过收集轻度认知功能障碍(MCI)、阿尔茨海默病(AD)和正常衰老(CN)患者的血浆样本,利用miRNA测序miRNA在人体血浆中的表达量,筛选差异表达miRNA,及进一步用qPCR检测,发现hsa-miR-106b-3p在MCI与CN组、AD与MCI组表达均出现显著降低(P<0.01);因此血浆hsa-miR-106b-3p可以作为新的AD早期血浆标志物,并通过该标志物制备AD临床预测qPCR试剂盒,用于AD早期(MCI阶段)的辅助诊断。
附图说明
图1为本发明的MCI/CN、AD/MCI差异表达分析结果,每个点代表一个miRNA,浅色点斜上方的深色点代表高表达,浅色点斜下方的深色点代表低表达。
图2为本发明的AD、MCI、正常对照患者提取的血浆miRNA高通量测序结果,选择adj.pvalue<0.05的miRNA绘制表达量热图。
图3为本发明的MCI与CN组、AD与CN组、AD与MCI组差异miRNA的维恩图。
图4为本发明的hsa-miR-106b-3p在AD、MCI、正常对照患者血浆中qPCR验证结果图。
图5为本发明的MCI、CN组血浆has-miR-106b-3p ROC曲线图。
具体实施方式
下面结合附图详细说明本发明的具体实施方式:
本发明提供一种阿尔茨海默病早期预测的标志物,所述的标志物为hsa-miR-106b-3p,所述标志物hsa-miR-106b-3p的核苷酸序列如下所示:RT:GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAGCAGCA;合成所述标志物hsa-miR-106b-3p的引物为:F:CCGCACTGTGGGTACTT;R:GTGCAGGGTCCGAGGT;标志物筛选方式如下:
(1)依据2011年NIA-AAMCI诊断标准和2014年IWG-2AD诊断标准,收集19名MCI患者、18名AD患者和20名正常人群的血浆,利用miRNA高通量测序,进一步筛选差异表达的microRNAs(adj.pvalue<0.05);
(2)筛选hsa-miR-106b-3p作为潜在AD早期血浆潜在生物标志物,利用AD、MCI、正常对照的血浆进行进一步qPCR检测,验证其表达水平;
(3)明确血浆hsa-miR-106b-3p表达水平可用于区分MCI、正常对照患者后,进一步生产hsa-miR-106b-3p检测试剂盒(荧光RT-PCR法)。
本发明提供一种阿尔茨海默病检测试剂盒,所述试剂盒包含以上所述的标志物hsa-miR-106b-3p。
本发明还提供了一种阿尔茨海默病早期预测标志物的用途,具体为所述标志物在制备阿尔茨海默病检测试剂盒中的应用。
本发明的术语说明:
本发明中,术语“表达水平”是指来自患者血浆miRNA的平均表达值(在RNA高通量测序、qPCR验证中),某个“表达水平”也可作为结果展示出这些转录物彼此的相对丰度,比如AD患者与健康对照血浆中的miRNA表达来评估。
本发明中,“miRNA”是内源性的具有调控功能的非编码RNA,其大小长度约为20—25个核苷酸,较长的miRNA基因初级转录物(primary miRNA)经过核内的Drosha核酸酶的剪切,先形成具有发夹结构的约70—90个碱基大小的单链RNA前体(pre-miRNA),经Exportin转运蛋白运输至细胞质内,再进一步被Dicer酶加工,最后生成成熟的miRNA(maturemiRNA)。
本发明中,术语“高通量测序”是指基于二代测序技术一次对几十万到几百万条DNA分子进行序列测定,然后对构建的miRNA文库进行比对,获得miRNA成熟体的计数(count),可用于后续差异表达分析。
本发明中,术语“qPCR”中文名为实时荧光定量PCR(Quantitative Real-timePCR)是一种将miRNA逆转录为cDNA,在cDNA扩增反应中,以荧光化学物质检测每次聚合酶链式反应(PCR)循环后产物总量,进而通过内参法(本发明用U6作为内参)对待测样品中的特定DNA序列进行定量分析的方法。
本发明中,术语“标志物”或“生物标志物”是指系统、器官、组织、细胞及亚细胞在某些生理或病理条件下结构或功能改变的生化指标,生物标志物可用于疾病诊断、判断疾病分期。
具体实验步骤:
1.分别选取18名AD、19名MCI、20名健康对照患者CN的外周血至EDTA抗凝管,一小时内1000转、10min、4℃条件下进行离心,然后将上层血浆保留,避免血细胞污染,然后在-80℃冰箱中进行保存。
采用miRNeasy Serum/Plasma Kit(Cat#217184,Qiagen)并且根据生产厂商提供的标准操作流程进行样品的total RNA抽提,抽提所得total RNA经Agilent2100Bioanalyzer(Agilent technologies Santa Clara,US)电泳质检合格后备用。对纯化后的Total RNA进行3’端接头连接,5’端接头连接、反转录、扩增、cDNA文库大小选择,纯化等步骤,完成测序样本文库构建。
Illumina第二代高通量测序技术共完成57个样本的RNA-seq测序实验,采用基因组GRCh38对测序结果进行比对,测序结果质控标准为每个样品提供测序后reads数约20M;碱基质量大于20(Q20)的比例不小于90%。为了使不同miRNA之间以及不同样本间的miRNA表达水平,将比对到每个miRNA的reads count转化为每百万的reads比对到外显子的每千碱基的fragments数(FPKM)。筛选在某一组(CN/MCI/AD)至少有10个样本的FPKM值大于1的miRNA用于下游差异分析,最终获得351个已知miRNA在57个样本中的表达数据。
应用edgeR进行样本间差异miRNA分析,得出p-value后进行多重假设检验校正,校正后的p-value即q-value。同时,我们根据FPKM值计算差异表达倍数,即Fold-change。差异miRNA筛选条件如下:1)q-value≤0.05;2)Fold-change≥0.5,MCI与CN组差异miRNA为13个,AD与CN组差异miRNA为11个,MCI与MCI组差异miRNA为7个。
2.筛选hsa-miR-106b-3p作为后续验证,按照上述步骤继续分离提取AD、MCI、健康对照患者的血浆,提取血浆中总RNA,利用紫外吸收法和酶标仪进行RNA浓度和纯度验证,利用RT-PCR和qPCR技术检测hsa-miR-106b-3p的表达变化情况,hsa-miR-106b-3p核苷酸序列如下所示:RT:GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAGCAGCA;hsa-miR-106b-3p引物:F:CCGCACTGTGGGTACTT;R:GTGCAGGGTCCGAGGT,通过miRNA加尾法逆转录进行目的miRNA扩增,用标准品制作标准曲线,根据标准曲线计算出每个血浆样本的hsa-miR-106b-3p拷贝数。与CN组相比,MCI患者血浆中hsa-miR-106b-3p表达量显著降低(mean±SEM,p值=0.0089);但与MCI组相比,AD患者血浆中hsa-miR-106b-3p表达量无明显变化。
3.制作ROC曲线评估血浆hsa-miR-106b-3p表达水平对诊断MCI的潜在实用性。我们的ROC分析显示,MCI与CN曲线下面积(AUC)值为0.765。这些获得的结果表明hsa-miR-106b-3p对MCI(AD早期)具有良好的诊断价值。
4.最后,制作hsa-miR-106b-3p试剂盒(荧光RT-PCR法)。
以上所述,仅是本发明的较佳实施例,并非对本发明的技术范围作任何限制,本行业的技术人员,在本技术方案的启迪下,可以做出一些变形与修改,凡是依据本发明的技术实质对以上的实施例所作的任何修改、等同变化与修饰,均仍属于本发明技术方案的范围内。
Claims (5)
1.一种阿尔茨海默病早期预测的标志物,其特征在于,所述的标志物为hsa-miR-106b-3p。
2.根据权利要求1所述的一种阿尔茨海默病早期预测的标志物,其特征在于,所述标志物hsa-miR-106b-3p的核苷酸序列如下所示:
RT:GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAGCAGCA。
3.根据权利要求1所述的一种阿尔茨海默病早期预测的标志物,其特征在于,合成所述标志物hsa-miR-106b-3p的引物为:
F:CCGCACTGTGGGTACTT;R:GTGCAGGGTCCGAGGT。
4.一种阿尔茨海默病检测试剂盒,其特征在于,所述试剂盒包含如权利要求2或3所述的标志物hsa-miR-106b-3p。
5.如权利要求3所述标志物在制备阿尔茨海默病检测试剂盒中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011571363.2A CN112458165A (zh) | 2020-12-27 | 2020-12-27 | 一种阿尔茨海默病的预测标志物、检测试剂盒及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011571363.2A CN112458165A (zh) | 2020-12-27 | 2020-12-27 | 一种阿尔茨海默病的预测标志物、检测试剂盒及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112458165A true CN112458165A (zh) | 2021-03-09 |
Family
ID=74803402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011571363.2A Pending CN112458165A (zh) | 2020-12-27 | 2020-12-27 | 一种阿尔茨海默病的预测标志物、检测试剂盒及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112458165A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2011029903A1 (en) * | 2009-09-10 | 2011-03-17 | Flemming Velin | Method for the preparation of micro-rna and its therapeutic application |
CN104011210A (zh) * | 2011-10-11 | 2014-08-27 | 布里格姆及妇女医院股份有限公司 | 神经退行性病症中的microRNA |
CN104981548A (zh) * | 2012-11-16 | 2015-10-14 | 西门子公司 | 用于阿尔茨海默氏病的诊断性miRNA标志物 |
CA2997947A1 (en) * | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
CN109055541A (zh) * | 2018-09-26 | 2018-12-21 | 上海市精神卫生中心(上海市心理咨询培训中心) | Ad所致mci诊断标志物及其应用 |
WO2019031595A1 (ja) * | 2017-08-10 | 2019-02-14 | 国立大学法人京都大学 | 神経前駆細胞の選別方法 |
CN110559454A (zh) * | 2019-09-29 | 2019-12-13 | 中山大学孙逸仙纪念医院 | 一种用于诊疗阿尔兹海默症的纳米复合药物 |
CN110791560A (zh) * | 2019-11-06 | 2020-02-14 | 中国医学科学院医药生物技术研究所 | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 |
-
2020
- 2020-12-27 CN CN202011571363.2A patent/CN112458165A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2011029903A1 (en) * | 2009-09-10 | 2011-03-17 | Flemming Velin | Method for the preparation of micro-rna and its therapeutic application |
CN102573856A (zh) * | 2009-09-10 | 2012-07-11 | 弗莱明·韦林 | 用于制备微小rna 的方法及其治疗性应用 |
CN104011210A (zh) * | 2011-10-11 | 2014-08-27 | 布里格姆及妇女医院股份有限公司 | 神经退行性病症中的microRNA |
US20180023142A1 (en) * | 2011-10-11 | 2018-01-25 | The Brigham And Women`S Hospital, Inc. | Micrornas in neurodegenerative disorders |
CN104981548A (zh) * | 2012-11-16 | 2015-10-14 | 西门子公司 | 用于阿尔茨海默氏病的诊断性miRNA标志物 |
CA2997947A1 (en) * | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
WO2019031595A1 (ja) * | 2017-08-10 | 2019-02-14 | 国立大学法人京都大学 | 神経前駆細胞の選別方法 |
CN109055541A (zh) * | 2018-09-26 | 2018-12-21 | 上海市精神卫生中心(上海市心理咨询培训中心) | Ad所致mci诊断标志物及其应用 |
CN110559454A (zh) * | 2019-09-29 | 2019-12-13 | 中山大学孙逸仙纪念医院 | 一种用于诊疗阿尔兹海默症的纳米复合药物 |
CN110791560A (zh) * | 2019-11-06 | 2020-02-14 | 中国医学科学院医药生物技术研究所 | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 |
Non-Patent Citations (5)
Title |
---|
HE LIU: ""Colorectal cancer-derived exosomal miR-106b-3p promotes metastasis by down-regulating DLC-1 expression"", 《CLINICAL SCIENCE》 * |
L CHENG等: ""Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment"", 《MOLECULAR PSYCHIATRY》 * |
MENG LI WANG等: ""MicroRNAs in Alzheimer’s Disease"", 《FRONTIERS IN GENETICS》 * |
VIRGINIE BOTTERO等: "Meta-analysis of gene expression changes in the blood of patients with mild cognitive impairment and Alzheimer\'s disease dementia" * |
YUQUAN WU等: "Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer’s Disease" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2733219B1 (en) | Diagnostic miRNA markers for Alzheimer | |
US9388470B2 (en) | Serum or plasma microRNA as biomarkers for non-small cell lung cancer | |
US9637793B2 (en) | Pancreatic cancer markers, and detecting methods, kits, biochips thereof | |
JP6667813B2 (ja) | アルツハイマー病又は軽度認知症の検出を補助する方法 | |
CN107338324B (zh) | 用于诊断不明原因复发性流产的血清lncRNA标志物、引物组及应用和试剂盒 | |
CN109055541B (zh) | Ad所致mci诊断标志物及其应用 | |
WO2021000893A1 (en) | Mirna receptivity analysis of the endometrium | |
CN104480106B (zh) | 检测轻度认知障碍患者血清/血浆微小rna标志物及其应用 | |
CN108841949B (zh) | 帕金森病早期检测和诊断试剂盒及装置 | |
CN108977533B (zh) | 一种用于预测慢性乙肝炎症损伤的miRNA组合物 | |
CN112980941B (zh) | 一种诊断受试者是否患阿尔茨海默病的试剂盒及其用途 | |
CN112458165A (zh) | 一种阿尔茨海默病的预测标志物、检测试剂盒及应用 | |
US10815528B2 (en) | MiRNAs as non-invasive biomarkers for inflammatory bowel disease | |
WO2021142417A2 (en) | Systems for detecting alzheimer's disease | |
CN113025707A (zh) | 生物标志物在制备诊断湿热困脾型2型糖尿病的产品中的应用、试剂盒 | |
CN112522391A (zh) | hsa_circ_0008961作为痛风诊断标志物的应用 | |
WO2015091897A1 (en) | Determination of platelet-mirnas | |
EP3369829B1 (en) | Methods for detecting attention-deficit/hyperactivity disorder | |
CN112646876B (zh) | 用于银屑病诊断的miRNA及其应用 | |
KR102548285B1 (ko) | 특발성 신증후군 진단용 바이오마커 조성물 및 이의 용도 | |
CN106544435A (zh) | 检测miR‑206所需逆转录引物对在制备预测试剂盒中的应用 | |
CN115725713A (zh) | 检测轻度认知障碍的微小rna标志物及其应用 | |
Morar et al. | Altered microRNA expression in patients with sarcoidosis | |
KR20220052474A (ko) | 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도 | |
Vachev et al. | Alterations of miR-320 family members as a novel diagnostic biomarkers in peripheral blood of schizophrenia patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210309 |